Enter B and W: Two new meningococcal vaccine programmes launched

Archives of Disease in Childhood

Volumn 101, Issue 1, 2016, Pages 91-95

  Ladhani, Shamez N ^a   Ramsay, Mary ^a   Borrow, Ray ^b   Riordan, Andrew ^c   Watson, John M ^d   Pollard, Andrew J ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^d Department of Health ^*  (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; VACCINE;

CHILDHOOD DISEASE; ENDEMIC DISEASE; EPIDEMIC; HEALTH PROGRAM; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; ADOLESCENT; AGE DISTRIBUTION; CHILD; ENGLAND; HUMAN; INFANT; MENINGOCOCCAL INFECTIONS; NEWBORN; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; AGE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; ENGLAND; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; UNITED KINGDOM; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84951936609     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2015-308928     Document Type: Review

References (21)

1. Public Health England. Meningococcal B (MenB) vaccination programme. 2015. https://www.gov.uk/government/publications/menb-vaccination-introduction-from-1-september-2015
2. Lucidarme J, Hill DMC, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect 2015;71:544-52.
3. Ladhani S, Pebody RG, Ramsay ME, et al. Continuing impact of infectious diseases on childhood deaths in England and Wales, 2003-2005. Pediatr Infect Dis J 2010;29:310-13.
4. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7.
5. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012;30:3710-16.
6. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362:1511-20.
7. Arnold R, Galloway Y, McNicholas A, et al. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011;29:7100-6.
8. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013;13:416-25.
9. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31:4968-74.
10. ® meningococcal B vaccine in the UK. 2014. https://www.gov. uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement
11. Christensen H, Trotter CL, Hickman M, et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ 2014;349:g5725.
12. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012;307:573-82.
13. Prymula R, Esposito S, Zuccotti GV, et al. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother 2014;10:1993-2004.
14. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67.
15. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014;383:40-7.
16. Hahné SJ, Gray SJ, Jean-François, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002;359:582-3.
17. Valenzuela MT, Moreno G, Vaquero A, et al. [Emergence of W135 meningococcal serogroup in Chile during 2012]. Rev Med Chil 2013;141:959-67.
18. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W ST-11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis 2015;60:578-85.
19. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010;10:853-61.
20. Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA 2001;286:688-93.
21. Nelson SJ, Charlett A, Orr HJ, et al. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect 2001;126:211-17.